These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 9974369

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Low molecular weight heparin (nadroparine) versus oral anticoagulant (acenocoumarol) in the long-term treatment of deep venous thrombosis: comparison of efficacy, safety and hospitalisation period in 105 patients.
    Mazokopakis EE, Vrentzos GE, Ganotakis ES.
    Curr Med Res Opin; 2003; 19(6):565-6. PubMed ID: 14594529
    [Abstract] [Full Text] [Related]

  • 4. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T, Wolf H, Michaelis HC, Wagner W, Hoffmann A, Schmidt A, Beck H.
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.
    Nurmohamed MT, van Riel AM, Henkens CM, Koopman MM, Que GT, d'Azemar P, Büller HR, ten Cate JW, Hoek JA, van der Meer J, van der Heul C, Turpie AG, Haley S, Sicurella A, Gent M.
    Thromb Haemost; 1996 Feb; 75(2):233-8. PubMed ID: 8815566
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M, Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators.
    N Engl J Med; 2003 Jul 10; 349(2):146-53. PubMed ID: 12853587
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prevention of recurrences after deep venous thrombosis: role of low-molecular-weight heparins.
    Pini M.
    Semin Thromb Hemost; 1997 Jul 10; 23(1):51-4. PubMed ID: 9156411
    [Abstract] [Full Text] [Related]

  • 15. Low molecular weight heparin for deep vein thrombosis in glioma patients.
    Schmidt F, Faul C, Dichgans J, Weller M.
    J Neurol; 2002 Oct 10; 249(10):1409-12. PubMed ID: 12382158
    [Abstract] [Full Text] [Related]

  • 16. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P, Laporte-Simitsidis S, Navarro C, Sié P, d'Azemar P, Necciari J, Duret JP, Gaud C, Decousus H, Boneu B.
    Thromb Haemost; 1998 Jun 10; 79(6):1162-5. PubMed ID: 9657442
    [Abstract] [Full Text] [Related]

  • 17. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group.
    Hamulyák K, Lensing AW, van der Meer J, Smid WM, van Ooy A, Hoek JA.
    Thromb Haemost; 1995 Dec 10; 74(6):1428-31. PubMed ID: 8772214
    [Abstract] [Full Text] [Related]

  • 18. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J, Riess H, Büller HR, Brom J, Weidinger G, Huisman MV.
    Haematologica; 2003 Oct 10; 88(10):1157-62. PubMed ID: 14555312
    [Abstract] [Full Text] [Related]

  • 19. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov 10; 20(21):1553-62. PubMed ID: 10529323
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.